title: Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.
abstract: The recombinant CD3 immunotoxin, A-dmDT(390)-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3epsilon monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.
authors.affiliation: Scott & White Cancer Research Institute, 5701 S. Airport Road, Temple, TX 76502, USA. afrankel@swmail.sw.org
authors.forename: A E
authors.initials: AE
authors.lastname: Frankel
authors.forename: S L
authors.initials: SL
authors.lastname: Zuckero
authors.forename: A A
authors.initials: AA
authors.lastname: Mankin
authors.forename: M
authors.initials: M
authors.lastname: Grable
authors.forename: K
authors.initials: K
authors.lastname: Mitchell
authors.forename: Y J
authors.initials: YJ
authors.lastname: Lee
authors.forename: D M
authors.initials: DM
authors.lastname: Neville
authors.forename: J H
authors.initials: JH
authors.lastname: Woo
mesh_terms: D000368:Aged; D017252:CD3 Complex / Q000276:immunology; D004167:Diphtheria Toxin / Q000009:adverse effects / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects / Q000627:therapeutic use*; D016399:Lymphoma, T-Cell / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000628:therapy*
chemical_list: D017252:CD3 Complex; D004167:Diphtheria Toxin; D000922:Immunotoxins; D011993:Recombinant Fusion Proteins